SCHEMBL1709962

SCHEMBL1709962

COc1c(C)cccc1I

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPK1 P28482 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
SCN4A P35499 7/20 0.36
CYP1A2 P05177 3/20 0.36
LMNA P02545 3/20 0.36
SCN1A P35498 2/20 0.36
SCN5A Q14524 2/20 0.36
SCN9A Q15858 2/20 0.36
TSHR P16473 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
NFKB1 P19838 2/20 0.36
CYP2C9 P11712 1/20 0.36
KCNK3 O14649 1/20 0.36
CACNA1F O60840 1/20 0.36
KCNK2 O95069 1/20 0.36
GBA1 P04062 1/20 0.36
MAOA P21397 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3648629 0.85 SMN1; SMN2 (0.46) ALDH1A1KDM4EMAPK1SMN1; SMN2LMNA
SCHEMBL145464 0.82 ALDH1A1 (0.48) ALDH1A1KDM4EMAPK1SMN1; SMN2SCN4A
SCHEMBL10702633 0.78 SMN1; SMN2 (0.40) ALDH1A1KDM4EMAPK1SMN1; SMN2CYP1A2
Methyl Alcohol SCHEMBL28303521 0.77 ALDH1A1 (0.46) ALDH1A1KDM4EMAPK1SMN1; SMN2SCN4A
SCHEMBL4156068 0.76 SMN1; SMN2 (0.50) ALDH1A1KDM4EMAPK1SMN1; SMN2CYP1A2
SCHEMBL30350539 0.76 SMN1; SMN2 (0.50) ALDH1A1KDM4EMAPK1SMN1; SMN2CYP1A2
SCHEMBL16950837 0.76 SCN4A (0.41) ALDH1A1KDM4ESCN4ACYP1A2LMNA
SCHEMBL25839643 0.76 ENPP2 (0.47) ALDH1A1KDM4EMAPK1SMN1; SMN2MCL1
Cyanide SCHEMBL27893752 0.75 ALDH1A1 (0.42) ALDH1A1KDM4EMAPK1SMN1; SMN2SCN4A
SCHEMBL22664822 0.74 NQO2 (0.39) ALDH1A1KDM4EMAPK1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192622-A1 ANTI-SARS-COV-2 DRUG ONCOLYS BIOPHARMA, INC. (JP) 2023-06-22 US disclosed
WO-2023091746-A1 COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR INCYTE CORPORATION (US) 2023-05-25 WO disclosed
WO-2023284869-A1 SULFUR/PHOSPHORUS-CONTAINING ARYL COMPOUND AND APPLICATION THEREOF 南京明德新药研发有限公司 2023-01-19 WO disclosed
WO-2023283213-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORPORATION (US) 2023-01-12 WO disclosed
WO-2022268119-A1 SULFOXIMINE COMPOUND AND USE THEREOF 南京明德新药研发有限公司 2022-12-29 WO disclosed
WO-2019059161-A1 PYRIDONE COMPOUND AND AGRICULTURAL AND HORTICULTURAL GERMICIDE HAVING SAME AS ACTIVE INGREDIENT 三井化学アグロ株式会社 2019-03-28 WO disclosed
EP-2900645-A1 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION Bayer CropScience AG (DE) 2015-08-05 EP disclosed
US-20120316342-A1 THERAPEUTIC AGENT FOR HEPATITIS C ONCOLYS BIOPHARMA, INC. (JP) 2012-12-13 US disclosed
US-20120087896-A1 HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS PTC THERAPEUTICS, INC. 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192622-A1 ANTI-SARS-COV-2 DRUG ACE2, ACE, SARS1 ALDH1A1 3243/4885KDM4E 3160/4885MAPK1 855/4885
US-20120087896-A1 HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS UPF1, RIOX2, RNGTT ALDH1A1 959/4885KDM4E 1881/4885MAPK1 3414/4885
US-20120316342-A1 THERAPEUTIC AGENT FOR HEPATITIS C HAVCR2, SLC10A1, FABP1 ALDH1A1 251/4885KDM4E 4605/4885MAPK1 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.